Pharmaceuticals, Biotechnology & Life Sciences

AbbVie expands its philanthropic reach with “Birdies for Brain Health,” boosts scientific leadership via exosome‑based skincare, and reaffirms commitment to immunology, neuroscience, and oncology.

Explore why Sartorius AG outperformed the MDAX, boosting investors with a 15% annual return and solid growth in biotech and pharma.

Explore Bayer AG’s latest moves: litigation risks, Apollo partnership, and mixed quarterly results—all shaping investor sentiment and debt reduction plans.

Novo’s “Novo” rebrand fuels a pipeline from GLP‑1/GCGR dual agonists to CRISPR‑gene therapy, aiming to diversify beyond obesity and diabetes with fast‑track approvals.

Explore J&J’s new COPERNICUS lung‑cancer data: SC dosing, lower AEs, and potential market edge—can it boost revenue and payer value?

Danaher’s new $0.40 dividend shows a firm balancing steady cash flow with pipeline growth, patent‑cliff risk mitigation, and strategic M&A to drive long‑term value.

Takeda’s FDA priority review of oral TYK2 inhibitor Zasocitinib promises rapid, durable plaque psoriasis relief—especially for scalp and nail lesions—with a superior safety profile that could command a premium price.

Explore how Palliser Capital’s challenge to Recordati’s takeover exposes valuation gaps, governance risks, and impacts on drug access and R&D.

Argenx SE’s upcoming extraordinary meeting on 17 Sept focuses on governance, dividend, and audit decisions, offering investors insight into its biopharma strategy and long‑term growth potential.

AbbVie’s 2026 AGM: governance changes, new incentive plan, audited financials, and insights on Humira, Venclexta, bispecifics and future growth.